

# Review on Preparation and Evaluation of 300 mg Aspirin Tablet by Wet Granulation Method

Tambe Aditya<sup>1</sup>, Tarade Akshay<sup>2</sup>, Waghmare Rahul<sup>3</sup>, Dapkekar Sambhaji<sup>4</sup>, Prof. Datkhile Sachin<sup>5</sup>

Students, Samarth Institute of Pharmacy, Belhe, Maharashtra, India<sup>1,2</sup>

Department of Pharmaceutics, Samarth Institute of Pharmacy, Belhe, Maharashtra, India<sup>1,2,3</sup>

akshay.tarade2001@gmail.com

**Abstract:** The goal of the current study was to create aspirin tablets using the wet granulation method with less excipients and to evaluate how it performed against other brands. In addition to aspirin, the design formulation also included excipients such lactose, maize starch, and aerosil. The mixture was compressed using a single punch machine, and the tablets were then put through a series of tests (including ones for uniformity of weights, diameter and thickness, hardness, disintegration, dissolution, and drug assay), with the results being compared to those of some of the competing brands. The investigated formulation closely resembled the commercially available brands and complied with all official requirements. To create a solution that is affordable, additional research should be planned utilizing different active ingredients and excipients.[1]

**Keywords:** Aspirin, Acetyl salicylic acid, direct compression, Dissolution, Disintegration, Hardness. [2]

## REFERENCES

- [1]. Abbott F, Kassam J, Orr J, and K. Farrell, The effects of aspirin on valproic acid metabolism. Clin. Pharmacol. Ther. 1986; 40:94-100.
- [2]. Altman R, Bouillon F, Rouvier J, Raca R, de la Fuente, Favalaro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976; 72: 127-9.
- [3]. Amrein PC, Ellman L, Harris WH. ASPIRIN prolongation of bleeding time and perioperative blood loss. JAMA 1981; 245: 1825-8.
- [4]. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Br Med J 1988; 296: 320-1.
- [5]. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
- [6]. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Br Med J 1994; 308: 158-68.
- [7]. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. Br Med J 1994; 308: 235-46.
- [8]. Aspirin Myocardial Infarction Study Research Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980; 243: 661-9.
- [9]. Aspirin Myocardial Infarction Study Research Group: The aspirin myocardial infarction study: final results. Circulation 1980; 62 (Suppl V): V79-V84.
- [10]. Bailey JM. Prostacyclins, thromboxane and cardiovascular disease. Tr Biochem Sci 1979; 4: 68-71.
- [11]. Boston Collaborative Drug Surveillance Group. Regular aspirin intake and acute myocardial infarction. Br Med J 1974; 1: 440-3.
- [12]. Bousser MG, Eschwege E, Haguenu M, Lefauconnier JM, Thibault N, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 1983; 14:5-14.



**IJARSCT**

Impact Factor: **6.252**

**IJARSCT**

ISSN (Online) 2581-9429

**International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)**

**Volume 2, Issue 2, December 2022**

- [13]. Boyd EM. Analgesic abuse. Maximal tolerated daily doses of acetylsalicylic acid. CanMed Ass J 1968; 99: 790-8.
- [14]. Boyd EM. The acute oral toxicity of acetylsalicylic acid. Toxic Appl Pharmac 1959; 1: 229-39.